Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.
Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP.
Harris LN, et al. Among authors: iglehart jd.
Clin Cancer Res. 2007 Feb 15;13(4):1198-207. doi: 10.1158/1078-0432.CCR-06-1304.
Clin Cancer Res. 2007.
PMID: 17317830
Clinical Trial.